We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
A review of treatment options in HER2‐low breast cancer and proposed treatment sequencing algorithm.
- Authors
Roy, Arya Mariam; Kumarasamy, Vasanthan Muthusamy; Dhakal, Ajay; O'Regan, Ruth; Gandhi, Shipra
- Abstract
The expansion of the spectrum of human epidermal growth factor receptor 2 (HER2)‐status to HER2‐low, defined as HER2 expression of 1+ by immunohistochemistry (IHC) or 2+ by IHC without gene amplification, has made a major impact in the field of oncology. The HER2‐low expression has emerged as a targetable biomarker, and anti‐HER2 antibody‐drug conjugate trastuzumab deruxtecan has shown significant survival benefit in pretreated metastatic HER2‐low breast cancer (BC). With these recent data, the treatment algorithm for hormone receptor–positive and triple‐negative BC needs to be reconsidered, as approximately half of these BCs are HER2‐low. Although there are different therapeutic agents for hormone receptor–positive and hormone receptor–negative HER2‐low BCs, there is no consensus regarding the sequencing of these agents. In this article, the treatment options for HER2‐low BC are enumerated and a treatment sequencing algorithm based on the current clinical evidence proposed. The expansion of the spectrum of human epidermal growth factor receptor 2 (HER2)‐status to HER2‐low has made a major impact in the field of oncology. Because there is no consensus regarding the sequencing of the HER2‐targeting agents in HER2‐low breast cancers, the treatment options for HER2‐low breast cancer are enumerated and a treatment‐sequencing algorithm based on the current clinical evidence proposed.
- Subjects
EPIDERMAL growth factor receptors; HORMONE receptor positive breast cancer; BREAST cancer; CANCER treatment; GENE amplification; ANTIBODY-drug conjugates
- Publication
Cancer (0008543X), 2023, Vol 129, Issue 18, p2773
- ISSN
0008-543X
- Publication type
Article
- DOI
10.1002/cncr.34904